Timothy Collier (Presenter)
Cleveland HeartLab Inc
Bio: Ph.D. - 2010, NC State University under David Muddiman in Quantitative Proteomics Post-Doc - 2010-2013, Washington University in St. Louis under Ron Bose using quantitative mass proteomics to characterize signal dynamics of drug resistant breast cancers. Currently Research and Development Scientist at Cleveland Heartlab under Cory Bystrom developing new quantitative proteomic assays of diagnostic or prognostic value in Cardiovascular Health.
| Short Abstract This session is directed toward attendees new to mass spectrometry and its use for measuring of proteins and peptides (proteomics) in the clinical laboratory. It will be presented in three parts with questions and discussion welcomed after each. Part one of this session will present the definition of proteomics within the broader context of systems biology. We will also discuss the clinical proteomics workflow within the context of the clinical laboratory environment, and how information gathered from proteomic measurements can offer clinical insight into a patient’s state of health, compared and contrasted to genetic, metabolic, and other small molecule diagnostics. |
Long Abstract
This session is directed toward attendees new to mass spectrometry and its use for measuring of proteins and peptides (proteomics) in the clinical laboratory. It will be presented in three parts with questions and discussion welcomed after each. Part one of this session will present the definition of proteomics within the broader context of systems biology. We will also discuss the clinical proteomics workflow within the context of the clinical laboratory environment, and how information gathered from proteomic measurements can offer clinical insight into a patient’s state of health, compared and contrasted to genetic, metabolic, and other small molecule diagnostics.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | yes | Cleveland HeartLab, Inc. |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |